Karus Therapeutics Appoints New Head Of Clinical Development And Head Of Biology

Oxford, UK – 21 October 2014 – Karus Therapeutics ('Karus'), a leader in the development of innovative medicines for the treatment of inflammatory diseases and cancer, today announced that it has further strengthened its R&D team with two new appointments; Dr Simon Roitt, who joins as Head of Clinical Development and Dr Peter Finan, who has been appointed as Karus's Head of Biology.

Dr Roitt, who joined Karus in August, brings 20 years' of clinical development experience in the healthcare sector with previous senior roles at Roche, GE Healthcare and Biocompatibles International. His experience in leading clinical teams in global multifunctional pharma environments will be critical for his role at Karus where he will implement the Company's clinical development plans.

Dr Finan took up his new position as Head of Biology in September following an extensive career in the pharmaceutical industry, from target discovery through to early clinical development in oncology and inflammatory disease. He joins Karus from Novartis, where he held a number of senior roles over a period of 16 years, during which time he worked on, amongst others, the PI3K pathway. Karus's most advanced programme is a PI3K-p110ß/d dual inhibitor for the treatment of inflammatory disorders and Dr Finan's experience will help to accelerate the translation of this programme into the clinic. Commenting on the new appointments, Dr Simon Kerry, Chief Executive of Karus said: "As we develop the business, the recruitment of highly experienced senior talent to our team will be a critical success factor. Simon and Peter both bring valuable clinical and scientific expertise to the Company, to help drive our programmes towards the clinic."

Dr Roitt, Head of Clinical Development added: "It's an exciting time to be joining Karus, as the company's promising preclinical programmes move towards human trials. I look forward to contributing to the success of Karus's clinical programmes."

Dr Finan, Head of Biology added: "Having spent much of my recent career working in pharmaceutical R&D, I am looking forward to adding my experience to the excellent progress that Karus has already made in developing highly selective and effective inhibitors against important therapeutic targets, and to bringing best in class drugs to market."

- ENDS -

Notes To Editors

About Karus Therapeutics

Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer. The Company's scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed. The UK-based Company is privately-held with a strong financial track record and experienced investors, including SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group. For further information please visit www.karustherapeutics.com

Issued for and on behalf of Karus Therapeutics by Instinctif Partners.

For more information please contact:
Instinctif Partners
Dr Christelle Kerouedan / Rosanna Forrest
Tel: +44 (0) 20 7457 2020
Email: [email protected] 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.